Literature DB >> 16631011

Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation.

Frank C Caira1, Stuart R Stock, Thomas G Gleason, Edwin C McGee, Jie Huang, Robert O Bonow, Thomas C Spelsberg, Patrick M McCarthy, Shahbudin H Rahimtoola, Nalini M Rajamannan.   

Abstract

OBJECTIVES: The goal of this research was to define the cellular mechanisms involved in myxomatous mitral valve disease and calcific aortic valve disease and to redefine the term degenerative valve disease in terms of an active cellular biology.
BACKGROUND: "Degenerative" valvular heart disease is the primary cause of regurgitant and stenotic valvular lesion in the U.S. However, the signaling pathways are not known. We hypothesize that valve degeneration occurs due to an osteoblastic differentiation process mediated by the low-density lipoprotein receptor-related protein 5 (Lrp5) signaling pathway to cause valve thickening.
METHODS: We examined human diseased valves: myxomatous mitral valves (n = 23), calcified tricuspid aortic valves (n = 27), calcified bicuspid aortic valves (n = 23), and control tissue from mitral and aortic valves (n = 40). The valves were examined by reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry for signaling markers important in osteoblast differentiation: Sox9 and Cbfa1 (transcription factors for osteoblast differentiation); Lrp5 and Wnt3 (osteoblast differentiation signaling marker), osteopontin and osteocalcin (osteoblast endochrondral bone matrix proteins), and proliferating cell nuclear antigen (a marker of cell proliferation). Cartilage development and bone formation was measured by Alcian blue stain and Alizarin red stain. Computed Scano MicroCT-40 (Bassersdorf, Switzerland) analysis measured calcium burden.
RESULTS: Low-density lipoprotein receptor-related protein 5, osteocalcin, and other osteochrondrogenic differentiation markers were increased in the calcified aortic valves by protein and gene expression (p > 0.001). Sox9, Lrp5 receptor, and osteocalcin were increased in myxomatous mitral valves by protein and gene expression (p > 0.001). MicroCT was positive in the calcified aortic valves and negative in the myxomatous mitral valves.
CONCLUSIONS: The mechanism of valvular heart disease involves an endochondral bone process that is expressed as cartilage in the mitral valves and bone in the aortic valves. Up-regulation of the Lrp5 pathway may play a role in the mechanism for valvular heart disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631011      PMCID: PMC3951851          DOI: 10.1016/j.jacc.2006.02.040

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  The floppy, myxomatous mitral valve, mitral valve prolapse, and mitral regurgitation.

Authors:  C F Wooley; P B Baker; A J Kolibash; J W Kilman; E A Sparks; H Boudoulas
Journal:  Prog Cardiovasc Dis       Date:  1991 May-Jun       Impact factor: 8.194

2.  Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; Frank Caira; Stuart R Stock; Thomas C Spelsberg
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

3.  The cDNA cloning and RNA distribution of bovine osteopontin.

Authors:  J M Kerr; L W Fisher; J D Termine; M F Young
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

4.  Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves.

Authors:  E Rabkin; M Aikawa; J R Stone; Y Fukumoto; P Libby; F J Schoen
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

5.  Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; Margaret Springett; Thomas C Sebo; Marek Niekrasz; Joseph P McConnell; Ravinder J Singh; Neil J Stone; Robert O Bonow; Thomas C Spelsberg
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

6.  Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve.

Authors:  N M Rajamannan; M Subramaniam; S R Stock; N J Stone; M Springett; K I Ignatiev; J P McConnell; R J Singh; R O Bonow; T C Spelsberg
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

7.  Human aortic valve calcification is associated with an osteoblast phenotype.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; David Rickard; Stuart R Stock; Janis Donovan; Margaret Springett; Thomas Orszulak; David A Fullerton; A J Tajik; Robert O Bonow; Thomas Spelsberg
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

8.  Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: an extracellular matrix and echocardiographic study.

Authors:  K Jane Grande-Allen; Allen G Borowski; Richard W Troughton; Penny L Houghtaling; Nicholas R Dipaola; Christine S Moravec; Ivan Vesely; Brian P Griffin
Journal:  J Am Coll Cardiol       Date:  2005-01-04       Impact factor: 24.094

9.  Quantitative structural analysis of collagen in chordae tendineae and its relation to floppy mitral valves and proteoglycan infiltration.

Authors:  P Whittaker; D R Boughner; D G Perkins; P B Canham
Journal:  Br Heart J       Date:  1987-03

10.  Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading.

Authors:  K Jane Grande-Allen; Anthony Calabro; Vishal Gupta; Thomas N Wight; Vincent C Hascall; Ivan Vesely
Journal:  Glycobiology       Date:  2004-03-24       Impact factor: 4.313

View more
  131 in total

1.  Cholesterol in vascular and valvular calcification.

Authors:  L L Demer
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

Review 3.  The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS.

Authors:  Sammy Elmariah; Emile R Mohler
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

4.  Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis.

Authors:  Su-Li Cheng; Jian-Su Shao; Linda R Halstead; Kathryn Distelhorst; Oscar Sierra; Dwight A Towler
Journal:  Circ Res       Date:  2010-05-20       Impact factor: 17.367

5.  Aortic stenosis: An update.

Authors:  Sangeetha Nathaniel; Shreyas Saligram; Antony Leslie Innasimuthu
Journal:  World J Cardiol       Date:  2010-06-26

Review 6.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

7.  Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors:  S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

8.  Approach to the patient with bicuspid aortic valve and ascending aorta aneurysm.

Authors:  José T Ortiz; David D Shin; Nalini M Rajamannan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

Review 9.  Imaging of inflammation and calcification in aortic stenosis.

Authors:  Marc R Dweck; Nikhil V Joshi; James H F Rudd; David E Newby
Journal:  Curr Cardiol Rep       Date:  2013-01       Impact factor: 2.931

10.  Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease.

Authors:  Kevin Bosse; Chetan P Hans; Ning Zhao; Sara N Koenig; Nianyuan Huang; Anuradha Guggilam; Stephanie LaHaye; Ge Tao; Pamela A Lucchesi; Joy Lincoln; Brenda Lilly; Vidu Garg
Journal:  J Mol Cell Cardiol       Date:  2013-04-11       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.